Literature DB >> 17310844

IL-15 an immunoregulatory and anti-cancer cytokine. Recent advances.

L N Shanmugham1, C Petrarca, S Frydas, J Donelan, M L Castellani, W Boucher, B Madhappan, S Tete', K Falasca, P Conti, J Vecchiet.   

Abstract

Interleukins are mediators of inflammation, immunity and cancer. IL-15 is a cytokine produced by several leukocytes including phagocytes in response to infections and other signals that trigger innate immunity. IL-15 has many homologies to interleukin-2 (IL-2) and like IL-2, stimulates NK cells. This cytokine acts also on memory CD8+ T-cell. IL-15, therefore acts, probably through selective inhibition of tumor promoting molecules, as a new compound for the adjuvant treatment of solid tumors. In this review we propose a newly revised mechanism of interleukin 15 in inflammation and cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17310844

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


  17 in total

1.  Characterization of recombinant human IL-15 deamidation and its practical elimination through substitution of asparagine 77.

Authors:  David F Nellis; Dennis F Michiel; Man-Shiow Jiang; Dominic Esposito; Richard Davis; Hengguang Jiang; Angela Korrell; George C Knapp; Lauren E Lucernoni; Roy E Nelson; Emily M Pritt; Lauren V Procter; Mark Rogers; Terry L Sumpter; Vinay V Vyas; Timothy J Waybright; Xiaoyi Yang; Amy M Zheng; Jason L Yovandich; John A Gilly; George Mitra; Jianwei Zhu
Journal:  Pharm Res       Date:  2011-10-19       Impact factor: 4.200

2.  Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization.

Authors:  Y Nakamoto; E Mizukoshi; M Kitahara; F Arihara; Y Sakai; K Kakinoki; Y Fujita; Y Marukawa; K Arai; T Yamashita; N Mukaida; K Matsushima; O Matsui; S Kaneko
Journal:  Clin Exp Immunol       Date:  2010-11-19       Impact factor: 4.330

3.  Adoptive cell therapy of patient-derived renal cell carcinoma xenograft model with IL-15-induced γδT cells.

Authors:  Baofu Zhang; Huizhong Li; Wenbin Liu; Hui Tian; Liantao Li; Chao Gao; Junnian Zheng
Journal:  Med Oncol       Date:  2021-02-18       Impact factor: 3.064

Review 4.  Receptor-directed therapy of T-cell leukemias and lymphomas.

Authors:  John C Morris; Thomas A Waldmann; John E Janik
Journal:  J Immunotoxicol       Date:  2008-04       Impact factor: 3.000

Review 5.  The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.

Authors:  Lana E Kandalaft; Nathan Singh; John B Liao; Andrea Facciabene; Jonathan S Berek; Daniel J Powell; George Coukos
Journal:  Gynecol Oncol       Date:  2009-12-02       Impact factor: 5.482

Review 6.  Antibody-based therapy of leukaemia.

Authors:  John C Morris; Thomas A Waldmann
Journal:  Expert Rev Mol Med       Date:  2009-09-30       Impact factor: 5.600

7.  The association of interleukin-16 gene polymorphisms with IL-16 serum levels and risk of nasopharyngeal carcinoma in a Chinese population.

Authors:  Xue Qin; Qiliu Peng; Xiaoxia Lao; Zhiping Chen; Yu Lu; Xianjun Lao; Cuiju Mo; Jingzhe Sui; Junrong Wu; Limin Zhai; Shi Yang; Shan Li; Jinmin Zhao
Journal:  Tumour Biol       Date:  2013-10-08

8.  Interleukin-16 polymorphisms as new promising biomarkers for risk of gastric cancer.

Authors:  Seyed Mohammad Hossein Kashfi; Faegheh Behboudi Farahbakhsh; Ehsan Nazemalhosseini Mojarad; Kazem Mashayekhi; Pedram Azimzadeh; Sara Romani; Shaghayegh Derakhshani; Habib Malekpour; Hamid Asadzadeh Aghdaei; Mohammad Reza Zali
Journal:  Tumour Biol       Date:  2015-09-07

9.  IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function.

Authors:  Daniel A Vallera; Martin Felices; Ron McElmurry; Valarie McCullar; Xianzheng Zhou; Joerg Uwe Schmohl; Bin Zhang; Alexander J Lenvik; Angela Panoskaltsis-Mortari; Michael R Verneris; Jakub Tolar; Sarah Cooley; Daniel J Weisdorf; Bruce R Blazar; Jeffrey S Miller
Journal:  Clin Cancer Res       Date:  2016-02-04       Impact factor: 12.531

10.  Interleukin-16 rs4778889 polymorphism contributes to the development of renal cell cancer in a Chinese population.

Authors:  Zongping Wang; Yipeng Xu; Shaoxing Zhu
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.